US equities |
NVDA $239.79 ▲+2.50% SPCX $169.65 ▲+6.72% MU $1,060.62 ▼-1.33% TSLA $380.90 ▲+2.78% SNDK $1,693.69 ▼-1.53% MSFT $528.48 ▲+2.11% INTC $116.50 ▼-2.37% META $743.74 ▲+2.15%
FinancialContent

Appili Therapeutics Inc (OP:APLIF)

0.0041 -0.0025 (-37.88%)
Delayed Quote Updated: 3:15 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Appili Therapeutics Inc

< Previous 1 2 3 Next >
News headline image
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
From Aditxt, Inc.
Via Business Wire
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Strengthens Leadership with Appointment of Governance Expert Sylvia Hermina to Board
Via Investor Brand Network
News headline image
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves Closer to Evofem Acquisition with Final Investment Milestone
Via Investor Brand Network
News headline image
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Hosts Virtual Fireside Chat to Discuss Evofem Acquisition and Future Strategic Plans
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Acquisition Target Plans Special Meeting of Shareholders to Obtain Transaction Approval
Via Investor Brand Network
News headline image
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX), Evofem Announce Completion of Third Parent Equity Investment Under Amended Merger Agreement
Via Investor Brand Network
InvestorNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Announces Participation at the Upcoming Game Industry Conference
Via Investor Brand Network
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Releases Shareholder Update, Plans for Remainder of 2024
Via Investor Brand Network
News headline image
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval
Via Investor Brand Network
News headline image
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
From Aditxt, Inc.
Via Business Wire
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement
Via Investor Brand Network
News headline image
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics Sign Second Amendent to Acquisition Agreement
Via Investor Brand Network
News headline image
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
From Aditxt, Inc.
Via Business Wire
News headline image
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
From Aditxt, Inc.
Via Business Wire
News headline image
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
From Appili Therapeutics
Via Business Wire
News headline image
Appili Therapeutics Presents at the 10th International Tularemia Conference
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics – Press Release Correction
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
From Appili Therapeutics Inc.
Via Business Wire
News headline image
Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
From Appili Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 Next >